ATE27457T1 - 1,2,4-triazine und pyrazin-derivate. - Google Patents

1,2,4-triazine und pyrazin-derivate.

Info

Publication number
ATE27457T1
ATE27457T1 AT83301142T AT83301142T ATE27457T1 AT E27457 T1 ATE27457 T1 AT E27457T1 AT 83301142 T AT83301142 T AT 83301142T AT 83301142 T AT83301142 T AT 83301142T AT E27457 T1 ATE27457 T1 AT E27457T1
Authority
AT
Austria
Prior art keywords
triazine
pyrazine derivatives
gaba
triazines
diaryl
Prior art date
Application number
AT83301142T
Other languages
English (en)
Inventor
David Taiwai Wong
William Bryant Lacefield
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE27457T1 publication Critical patent/ATE27457T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16—Halogen atoms; Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Enzymes And Modification Thereof (AREA)
AT83301142T 1982-03-05 1983-03-03 1,2,4-triazine und pyrazin-derivate. ATE27457T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/354,982 US4513135A (en) 1982-03-05 1982-03-05 Diaryl-pyrazine derivatives affecting GABA binding
EP83301142A EP0088593B1 (de) 1982-03-05 1983-03-03 1,2,4-Triazine und Pyrazin-Derivate

Publications (1)

Publication Number Publication Date
ATE27457T1 true ATE27457T1 (de) 1987-06-15

Family

ID=23395746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83301142T ATE27457T1 (de) 1982-03-05 1983-03-03 1,2,4-triazine und pyrazin-derivate.

Country Status (22)

Country Link
US (2) US4513135A (de)
EP (1) EP0088593B1 (de)
JP (1) JPS58162582A (de)
KR (1) KR860000847B1 (de)
AT (1) ATE27457T1 (de)
AU (1) AU547581B2 (de)
CA (1) CA1195327A (de)
DD (1) DD207716A5 (de)
DE (1) DE3371786D1 (de)
DK (1) DK97283A (de)
ES (2) ES8404346A1 (de)
FI (1) FI830708L (de)
GB (1) GB2116179B (de)
GR (1) GR78459B (de)
HU (1) HU191368B (de)
IL (1) IL68002A (de)
NZ (1) NZ203428A (de)
PH (1) PH22535A (de)
PL (1) PL240871A1 (de)
PT (1) PT76312B (de)
RO (1) RO86320B (de)
ZA (1) ZA831387B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) * 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
EP0934061B3 (de) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba und dessen derivate zur schmerzbehandlung
TWI316055B (de) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (주) 비엔씨바이오팜 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
US20070003394A1 (en) * 2005-02-01 2007-01-04 Carey Paul G Anti-cross threading fastener
EP1871762A2 (de) * 2005-04-18 2008-01-02 Neurogen Corporation Substituierte heteroaryle als cb1-antagonisten
EP2275096A3 (de) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
TW201321353A (zh) * 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
IL311645B2 (en) * 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
EP3549935A4 (de) * 2016-11-30 2020-08-05 Mitsubishi Tanabe Pharma Corporation Verfahren zur herstellung von triazinverbindungen
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
EP3788050B1 (de) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-verknüpfte rapamycinanaloga als mtor-inhibitoren
PL3788049T3 (pl) 2018-05-01 2023-06-19 Revolution Medicines, Inc. Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
EP4531859A4 (de) 2022-05-25 2026-05-27 Revolution Medicines Inc Verfahren zur behandlung von krebs mit einem mtor-inhibitor
CN117304174B (zh) * 2022-06-20 2026-04-28 四川轻化工大学 一种5,6-二苯基吡嗪-2-氮杂环类化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172889A (en) * 1965-03-09 Process for the separation of z-methyl-
US3294638A (en) * 1961-06-05 1966-12-27 Warner Lambert Pharmaceutical Method and compositions employing 2-alkyl-3-piperidinopyrazines
CH480795A (de) * 1967-03-01 1969-11-15 Sandoz Ag Mittel zur Beeinflussung des Pflanzenwachstums
US3989831A (en) * 1974-01-31 1976-11-02 Eli Lilly And Company Topically-active anti-inflammatory 3-chloro-5,6-diaryl-1,2,4-triazines
US3979516A (en) * 1974-01-31 1976-09-07 Eli Lilly And Company Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines
US4013654A (en) * 1974-01-31 1977-03-22 Eli Lilly And Company 5,6-diaryl-1,2,4-triazines
US3948894A (en) * 1974-01-31 1976-04-06 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4081542A (en) * 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
GB1493998A (en) * 1975-06-03 1977-12-07 Beecham Group Ltd Propanolamine derivatives
US4008232A (en) * 1975-06-23 1977-02-15 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4082844A (en) * 1976-02-09 1978-04-04 Merck & Co., Inc. 6-chloro-2-(1-piperazinyl)pyrazine
US4018923A (en) * 1976-03-10 1977-04-19 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
US4021553A (en) * 1976-03-10 1977-05-03 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
US4190725A (en) * 1976-03-10 1980-02-26 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines
NL7802514A (nl) * 1977-03-09 1978-09-12 Fabre Sa Pierre 5,6-diaryl-1,2,4-triazinederivaten en werkwijze ter bereiding van deze verbindingen.
CH633541A5 (en) * 1977-05-17 1982-12-15 Diamond Shamrock Corp Pharmacologically active substituted 1,2,4-triazines and medicaments containing these triazines
US4157392A (en) * 1977-05-17 1979-06-05 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
US4251527A (en) * 1977-05-17 1981-02-17 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines

Also Published As

Publication number Publication date
RO86320B (ro) 1985-03-31
PT76312B (en) 1986-02-04
IL68002A0 (en) 1983-06-15
ES520340A0 (es) 1984-04-16
DK97283A (da) 1983-09-06
RO86320A (ro) 1985-03-15
DE3371786D1 (en) 1987-07-02
US4513135A (en) 1985-04-23
HU191368B (en) 1987-02-27
FI830708A7 (fi) 1983-09-06
DK97283D0 (da) 1983-02-28
US4585861A (en) 1986-04-29
KR860000847B1 (ko) 1986-07-09
ES8404346A1 (es) 1984-04-16
ZA831387B (en) 1984-10-31
DD207716A5 (de) 1984-03-14
GB8305846D0 (en) 1983-04-07
EP0088593A2 (de) 1983-09-14
ES526297A0 (es) 1985-04-16
ES8504173A1 (es) 1985-04-16
GR78459B (de) 1984-09-27
AU1202983A (en) 1983-09-08
PL240871A1 (en) 1984-06-18
FI830708A0 (fi) 1983-03-02
IL68002A (en) 1986-09-30
FI830708L (fi) 1983-09-06
PH22535A (en) 1988-10-17
GB2116179A (en) 1983-09-21
GB2116179B (en) 1985-09-11
PT76312A (en) 1983-04-01
JPS58162582A (ja) 1983-09-27
EP0088593A3 (en) 1984-05-23
CA1195327A (en) 1985-10-15
EP0088593B1 (de) 1987-05-27
AU547581B2 (en) 1985-10-24
NZ203428A (en) 1986-09-10
KR840004101A (ko) 1984-10-06

Similar Documents

Publication Publication Date Title
AU547581B2 (en) 1,2,4-triazine and pyrazine derivatives
FI932032A0 (fi) Kinazolinderivat foer oekande av antitumoeraktivitet
NO162124C (no) Forspent bjelke av trevirke.
ATE56968T1 (de) Substituierte oxo-piperazinyl-triazine und uvlicht stabilisierte zubereitungen.
FI904851A0 (fi) Radiomaerkta antikoagulantpeptider.
ES8203375A1 (es) Procedimiento de preparar triazoloquinoxalin-4-onas substi- tuidas antihipertensoras
JPS57116100A (en) Novel d-homosteroid
FI853624L (fi) 1-substituerade tetralinderivat, deras framstaellning och anvaendning.
BG45552A3 (bg) Метод за получаване на 2-фенил-хексахидро-1,2,4- триазин-3,5-диони
ATE41773T1 (de) 4,5-dihydro-4-oxo-2((2-transphenylcyclopropyl)amino>-3-furancarbonsaeuren und derivate davon.
BG36935A3 (en) Method for preparing benzodiazepine compounds
EP0116628A4 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
BG35043A3 (en) Method for preparing condensed asymmetric triazine derivatives
BG37839A3 (bg) Метод за получаване на производни на ортокондензиран пирол
EP0295350A3 (en) Use of n-û2-(diethylamino)ethyl¨-2-methoxy-4-û(1-h 4,5-dihydro-2-imidazolyl)amino¨-5-chlorobenzamide as an anxiolytic and antipsychotic agent
ES8507530A1 (es) Un procedimiento para la preparacion de aricoxicicloalcanolaminolaminoalquilen-aril-cetonas.
IT1170227B (it) Caviglia per l'assemblaggio di parti di mobili
ATE23151T1 (de) Derivate des 1,4-dihydropyridins.
ATE47863T1 (de) Makrolide derivate.
MX9202927A (es) [7-(3-amino disubstituidas)fenil]pirazolo[1,5-a]pirimidinas composicion farmaceutica que las contiene.
ES270130U (es) Union para perfiles tipo "v".
SE8201677L (sv) Med centerbord forsedd segelfarkost

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee